Walking the tightrope: a balanced discussion of the benefits and harms of extended duration anticoagulation for venous thrombo-embolism
- PMID: 36656796
- DOI: 10.1093/eurheartj/ehac731
Walking the tightrope: a balanced discussion of the benefits and harms of extended duration anticoagulation for venous thrombo-embolism
Conflict of interest statement
Conflict of interest: G.P. has received research support from Bristol-Myers Squibb/Pfizer Alliance, Bayer, Janssen, Alexion, Amgen and Boston Scientific Corporation paid to his institution and consulting fees from Bristol-Myers Squibb/Pfizer Alliance, Boston Scientific Corporation, Janssen, Namsa, Prairie Education and Research Cooperative, Boston Clinical Research Institute, and Amgen.
Comment on
-
Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score.Eur Heart J. 2023 Apr 7;44(14):1231-1244. doi: 10.1093/eurheartj/ehac776. Eur Heart J. 2023. PMID: 36648242 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources